AEGiS-GMHC: IN BRIEF: Tat Gene Inhibitor Trial Revisited

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

IN BRIEF: Tat Gene Inhibitor Trial Revisited

Gay Men's Health Crisis Treatment Issues, Vol. 5, No. 5 - June 20, 1991
David Barr

We reported in our last issue that further studies of the TAT gene inhibitor trial, which were scheduled at Johns Hopkins University were put on hold due to financial considerations of the sponsoring drug company, Hoffmann-La Roche. TAT is one of the most powerful genes on HIV, which aids in the reproduction of new virus particles once HIV has entered a new cell and taken over its DNA. The Tat inhibitor is designed to block the protein made by the TAT gene in hopes that if the protein is unavailable, formation of new virus particles will be halted. This trial was to be the only of its kind.

As we go to press, it has come to our attention that this important trial is back on schedule. According to sources at Hoffmann-La Roche was seeking a partner to help shoulder some of that cost. Although, to date, no such partner has been found, the company decided to restart the trial, after much community pressure. The actual protocol of the trial is still in development. For further information contact Linda Nerhood at (301) 955-3224.

Copyright (c) 1991 - Gay Men's Health Crisis, Inc. All rights reserved. Non-commercial reproduction is encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com

910620
GM050510

Copyright © 1991 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .